Diabetes mellitus has emerged as an important global public concern, affecting 422
million adults. In addition, it is expected that diabetes will become the 7th leading
cause of death by 2030 [
[1]
]. Another important fact is that its prevalence increases rapidly with aging. As
population ages and the rates of overweight or obese individuals continue to rise,
both the prevalence and burden of diabetes in the elderly is expected to increase
substantially over the next several decades. The prevalence of diabetes in the elderly
is high; current estimates indicate that in the US, 26.9% of people ≥65 years of age
are diagnosed with the condition [
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Projections of global mortality and burden of disease from 2002 to 2030.PLoS Med. 2016; 3: e442
- Center for Disease Control and Prevention.Control and Prevention. National diabetes fact sheet: national estimates and general information of diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta2011
- Treatment of type 2 diabetes mellitus in elderly patients.Rev Clin Esp. 2018; 218: 74-88
- California healthcare foundation/American Geriatrics Society panel on improving Care for Elders with diabetes. Guidelines for improving the care of the older person with diabetes mellitus.J Am Geriatr Soc. 2003; 51: S265-80
- Update on cognitive decline and dementia in elderly patients with diabetes.Diabetes Metab. 2014; 40: 331-337
- Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.Pharm Res. 2012; 29: 2104-2114
- The pharmacodynamics variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state.Diabetes. 2011; 60: A263
- Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal–bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.Lancet. 2012; 379: 1498-1507
- Efficacy and safety of Degludec versus Glargine in type 2 diabetes.N Engl J Med. 2017; 377: 723-732
- Insulin use in elderly adults: risk of hypoglycemia and strategies for care.J Am Geriatr Soc. 2012; 60: 1564-1570
Article info
Publication history
Published online: March 22, 2018
Accepted:
March 19,
2018
Received in revised form:
March 18,
2018
Received:
March 12,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
